Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020
Author:
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference29 articles.
1. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France;Le Pen;Eur J Health Econ,2003
2. Revealed and stated preferences of decision makers for priority setting in health technology assessment: a systematic review;Ghijben;Pharmacoeconomics,2018
3. The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian oncology drug review 2011-2017;Skedgel;Pharmacoeconomics,2018
4. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada;Clement;JAMA,2009
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High drug prices are not justified by industry’s spending on research and development;BMJ;2023-02-15
2. Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals;International Journal of Technology Assessment in Health Care;2022
3. Reimbursement and pricing for innovative drugs in France: identifying criteria to inform decision-making;PharmacoEconomics & Outcomes News;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3